TXMD· Health Care› Drug Manufacturers - Specialty & Generic

TherapeuticsMD, Inc.

Stage 4 · Declining · week 1

As of Oct 22, 2026, TherapeuticsMD is in Stage 4, the downtrend phase, now in its first week (since Oct 20, 2026). It closed at $1.85, 33.2% below its 52-week high and below its 200-day average, which is rising.

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. More about the company

$1.85

-2.63% today

$21.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is TXMD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 22w

S4 55w

S2 23w

S3 19w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 22w → S1 2w → S4 5w → S1 4w → S4 55w → S1 8w → S2 4w → S3 2w → S4 3w → S3 3w → S4 5w → S2 23w → S3 19w → S2 6w → S1 2w → S4 1w current

Total tracked: 164 weeks across 16 stage runs.

TXMD among Drug Manufacturers - Specialty & Generic13th of 84 by relative strength

All 84 →

Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CPIXCumberland Pharmaceuticals Inc.	Stage 2 · wk 23	98	+6.8%
2	ETONEton Pharmaceuticals, Inc.	Stage 2 · wk 30	97	−10.1%
3	ANIKAnika Therapeutics Inc.	Stage 2 · wk 15	96	+3.5%
4	IRWDIronwood Pharmaceuticals, Inc. Class A	Stage 3 · wk 3	96	−16.4%
5	TEVATeva Pharmaceutical Industries Limited	Stage 2 · wk 9	95	+3.1%
6	AMRXAmneal Pharmaceuticals, Inc. Class A	Stage 2 · wk 19	95	+5.9%
7	KNSAKiniksa Pharmaceuticals International, plc Class A	Stage 2 · wk 73	95	+6.2%
8	AMLXAmylyx Pharmaceuticals, Inc.	Stage 2 · wk 15	93	−6.6%
…13	TXMDTherapeuticsMD, Inc.	Stage 4 · wk 1	89	−14.7%

vs 52W High

-33.2%

$1.15 lo$2.77 hi

33.2% below 52W high, ongoing decline

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-12.9%

200 DMA: $2.13 · rising

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.21x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-14.7%

-10.2%

-15.1%

YTD

+12.1%

+58.1%

Scan Membership

Breakout Watch

Latest: 2025-06-24

2 appearances in last 60 days. First seen: 2021-02-12.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 1 · Vol 0.21x

2026-10-21S4

Wk 1 · Vol 0.23x

2026-10-20S41→4

Wk 1 · Vol 0.49x

2026-10-19S1

Wk 3 · Vol 4.79x

2026-10-16S1

Wk 2 · Vol 1.33x

2026-10-15S1

Wk 2 · Vol 0.74x

2026-10-14S1

Wk 2 · Vol 0.28x

2026-10-13S1

Wk 2 · Vol 1.19x

2026-10-12S1

Wk 2 · Vol 0.57x

2026-10-09S1

Wk 1 · Vol 0.41x

2026-10-08S1

Wk 1 · Vol 0.56x

2026-10-07S1

Wk 1 · Vol 1.77x

Moving averages & range

50 DMA

$2.08

200 DMA

$2.13

52W High

$2.77

52W Low

$1.15

5D Low

$1.85

Resistance levels (recent highs)

20d High

$2.09

60d High

$2.28

120d High

$2.29

250d High

$2.77

Next resistance

+13.0%

to 20d High

Earnings Growth (YoY)

-80.6%

Revenue -8.7%

ROE

-1.1%

Profit margin -6.6%

Dividend Yield

0.00%

P/B 0.8

TherapeuticsMD: quick answers

What stage is TherapeuticsMD in?

As of Oct 22, 2026, TherapeuticsMD (TXMD) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 20, 2026 and is in its first week there. What the four stages mean

Is TherapeuticsMD in an uptrend?

No. TherapeuticsMD is in a Stage 4 downtrend. It trades 12.9% below its 200-day average, which is rising.

How far is TherapeuticsMD from its 52-week high?

TherapeuticsMD closed at $1.85 on Oct 22, 2026, 33.2% below its 52-week high of $2.77. Its 52-week low is $1.15.

How has TherapeuticsMD performed over the past year?

As of Oct 22, 2026, TherapeuticsMD is up 58.1% over the past year and up 12.1% so far in 2026.

Which sector and industry is TherapeuticsMD in?

TherapeuticsMD is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.